enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

BOSTON & MONTREAL–(BUSINESS WIRE)–enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates….


Click here to view the original article.